Abstract According to the World Health Organization (WHO) report in 2023, arterial hypertension (HTN) remains one of the leading causes of global morbidity, with an estimated 1.3 billion individuals diagnosed worldwide. Among them, 42% were receiving antihypertensive treatment, and only 21% achieved adequate blood pressure control. In the United States, 47.7% of the adult population is diagnosed with hypertension, with prevalence increasing significantly with age [1,2]. Multiple factors such as lifestyle, body mass index (BMI), age, sex, genetics, and physical inactivity are well-documented contributors to hypertension, as evidenced by both international and local studies. Specifically, individuals classified as obese demonstrate a higher prevalence of hypertension based on BMI categorization.
However, in Mongolia, limited studies have investigated the contributing factors and treatment outcomes of hypertension, highlighting the necessity of this study.
A retrospective study was conducted by reviewing the medical records of 50 inpatients diagnosed with arterial hypertension (ICD-10 codes I10–I15) who were admitted to Sindura-Med Hospital between 2023 and 2024.
1. In patients with stage 1 and 2 arterial hypertensions, age, mean systolic and diastolic blood plessure, heart rate and elevated cholesterol levels were found to be correlated with body mass index (BMI). Among smokers, the risk of developing cardiovascular diseases is projected to increase over the next 10 years
2. In the hypertensive group aged 60 years and older, echocardiographic examination revealed structural and functional abnormalities.
3. In the pharmacological management of arterial hypertension, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, combination preparations, and diuretics were the most commonly prescribed medications.

Introduction: Globally, 10.5-25.9 million cases of pyelonephritis have been reported, and the nature of the disease is changing over time. In Mongolia, as of 2022 diseases of the genitourinary system has increased from the average of the last 10 years, and account for 9% of all diseases. The incidence rate by age group increased in all age groups in 2022 compared to 2013, with the largest increase in the age group over 65 with 2,104 cases. The basis of this study is to determine the use of PIM drugs based on the Beers criteria for the treatment of patients diagnosed with pyelonephritis in our country. To study the use of drugs by inpatients diagnosed with pyelonephritis (N10), (N11) in referral hospitals and the use of PIM drugs used in the treatment of elderly people. Methods: A retrospective descriptive study was conducted on the medical history of a total of 150 patients diagnosed with pyelonephritis (year 2023) at The State Secondary Central Hospital, The State Third Central Hospital, and Hovd Regional Medical Centers. Among the 150 inpatients who participated in our study, 14.3% (n=18) of 126 types of drugs were used for the treatment of pyelonephritis, and 85.7% (n=108) for the treatment of multimorbidity and supportive treatment. Inpatients used 11 types of PIM drugs according to Beers criteria. Nitrofurantoin 39% was used the most and amitriptyline 9.8% were the most used drugs affecting the central nervous system. Conclusion 11 types of drugs included in the inappropriate category for use in the elderly are risky and should not be selected. Among them, nitrofurantoin 39%, from NSAIDs ketoprofen 19.5%, ibuprofen 7.3% were most used. PIM drugs used for treatment in 2014 are still used in 2024, indicating the need for improved drug monitoring in the elderly